OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2025.15152 OL-30-3-15152 Articles Post-irradiation mastoid mucosa disease in patients with nasopharyngeal carcinoma after radiotherapy: A large-cohort and long-term study XieRui-Ling 1 2 3 * ChenSi-Yuan 4 * FengZheng-Kai 4 FengShao-Yan 4 HuaPeng 5 WuWen-Bin 1 2 3 4 DuanXiao-Tong 6 DuanChong-Yang 7 LinChao 8 LvBo 4 WuJin-Hui 1 2 3 YouRui 4 JiaWei-Hua 2 3 9 ChenMing-Yuan 2 4 LiuYou-Ping 4 Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China Nasopharyngeal Carcinoma Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, P.R. China Department of Otolaryngology, Head and Neck Surgery, General Hospital of Southern Theatre Command of People's Liberation Army, Guangzhou, Guangdong 510010, P.R. China Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China Department of Radiation Oncology, FuJian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China Correspondence to: Dr You-Ping Liu, Nasopharyngeal Carcinoma Center, The Fifth Affiliated Hospital of Sun Yat-sen University, 52 Meihua East Road, Zhuhai, Guangdong 519000, P.R. China, E-mail: liuyp78@mail.sysu.edu.cn Professor Wei-Hua Jia, School of Public Health, Sun Yat-sen University, 74 Zhongshan Road 2, Yuexiu, Guangzhou, Guangdong 510080, P.R. China, E-mail: jiawh@sysucc.org.cn

Contributed equally

 092025 23062025 30 3 406 11022025 09042025 Copyright: © 2025 Xie et al. 2025 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The aim of the present study was to investigate the incidence and risk factors for persistent severe mastoid mucosa disease (MMD), which has not been previously evaluated among patients with nasopharyngeal carcinoma (NPC) after radiotherapy (RT), to the best of our knowledge. Patients with NPC were identified from a prospective observational cohort between January 2010 and December 2015. Persistent Grade 2 MMD (PG2MMD) was defined as being present in more than half of all MRIs scanned at preset time intervals during an indefinite follow-up period. Overall, 1,238 of 1,410 eligible patients with RT-treated nonmetastatic NPC were evaluated. A total of 887 (71.6%) patients did not have MMD at diagnosis, but 746 (60.3%) patients had G2MMD at least once after RT. To identify the risk factors for PG2MMD, 817 patients with NPC without MMD pretreatment and nasopharyngeal recurrence from the greater cohort were analyzed. In this group, the incidences of G2MMD at 3, 6, 12, 24 and 60 months after RT were 26.2, 21.3, 21.4, 21.4 and 16.8%, respectively. The incidence of PG2MMD was 17.9% (146/817). Age >50 years [hazard ratio (HR), 1.699], female sex (HR, 1.594) and a mean dose of radiation to the mastoids (mastoid Dmean) >37.30 Gy (HR, 1.554) were the independent factors for PG2MMD (all P<0.05). In conclusion, in the large-scale NPC cohort with long-term follow-up, most patients were not diagnosed with MMD prior to treatment, but more than half of those patients experienced MMD at least once during follow-up. Of note, age >50 years, female sex and a high mastoid Dmean were positive independent risk factors for post-RT PG2MMD.

 mastoid nasopharyngeal carcinoma radiotherapy risk factor National Natural Science Foundation of China 82230034 82071024 82261160399 Key-Area Research and Development of Guangdong Province 2020B1111190001 Special Support Program for High-level Talents in Sun Yat-sen University Cancer Center, the Guangzhou Science and Technology Plan Project 202103010001 National Ten Thousand Talents Program Science and Technology Innovation Leading Talents 84000-41180005 Jiangxi Technology Innovation Guidance Program S2021KJHZH0161 Nanchang Regional Innovation System Construction Project 20212BDH80023 Guangdong Clinical Teaching Research Project 2021JD014 Guangdong Basic and Applied Basic Research Foundation 2022A1515111113 China Postdoctoral Science Foundation 2020M683116 This work was supported by the National Natural Science Foundation of China (grant nos. 82230034, 82071024 and 82261160399), the Key-Area Research and Development of Guangdong Province (grant no. 2020B1111190001), the Special Support Program for High-level Talents in Sun Yat-sen University Cancer Center, the Guangzhou Science and Technology Plan Project (grant no. 202103010001), the National Ten Thousand Talents Program Science and Technology Innovation Leading Talents (grant no. 84000-41180005), the Jiangxi Technology Innovation Guidance Program (grant no. S2021KJHZH0161), the Nanchang Regional Innovation System Construction Project (grant no. 20212BDH80023), the Guangdong Clinical Teaching Research Project (grant no. 2021JD014), the Guangdong Basic and Applied Basic Research Foundation (grant no. 2022A1515111113), and the China Postdoctoral Science Foundation (grant no. 2020M683116). The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. Introduction

Nasopharyngeal carcinoma (NPC) is a specific type of head and neck cancer and is endemic in East Asia and Southeast Asia (1). Clinically, radiotherapy (RT) is the primary treatment for NPC. As epithelial cells are radiation-sensitive, RT causes these cells to become degenerative and prone to desquamation, increasing the susceptibility to pathogenic organisms in the irradiated target regions (2). Diseases of the middle ear include eustachian tube dysfunction (ETD), otitis media with effusion (OME) and mastoiditis (2). After curative RT treatment for newly diagnosed head and neck cancer, the incidence of mastoiditis varies from 4.9 to 33% (2–4). The peak incidence of mastoiditis occurs within 6 months after RT before decreasing and stabilizing (3,5). Patients with mastoid mucosa disease (MMD) often have complaints including tinnitus, clogged ears and hearing loss. Hence, there is no doubt that these persistent conditions impair patients' quality of life. Mild mastoiditis is self-limited, but severe mastoiditis requires a visit to an otolaryngologist due to the risk of life-threatening complications such as sinus thrombosis (6,7). Mastoiditis reportedly induces intracranial abscesses in patients with NPC (8). Persistent severe MMD, which is frequently associated with chronic OME or mastoiditis, can have significant long-term consequences, including anatomical and structural damage, auditory deficits and neurological or cranial complications if left untreated or inadequately managed.

Few studies have focused on the risks of post-irradiation MMD, and to the best of our knowledge, no studies have investigated persistent MMD. Age (3), tumor invasion (3,9), radiation dose (2,5,10–12), time after radiation (3), chemotherapy (3) and chronic otitis media with effusion (2) are reported risk factors for post-irradiation mastoiditis. However, the risks of inflammation indicators, drug administration and targeted therapy in patients with MMD after RT have remained elusive. Furthermore, the long-term incidence of post-RT MMD has remained to be determined. Hence, in the present study, the incidence and risk of persistent MMD were explored in a large-scale and long-term follow-up cohort after exposure to radiation.

 Patients and methods <sec> <title>Study design

One of the goals of the GARTP study (ChiCTRROC-17012658), a prospective observational clinical trial, is to identify risk factors for radiation-induced normal tissue complications in patients with NPC (13). The present study included 1,238 eligible patients from the cohort of the GARTP study, for which 1,410 patients with non-metastatic NPC were recruited from Sun Yat-sen University Cancer Center (SYSUCC, Guangzhou, China) from January 2010 to December 2015. The inclusion criteria were as follows: i) Newly diagnosed NPC proven by histology; ii) initial diagnostic magnetic resonance imaging (MRI) available at SYSUCC; iii) medical records available for review; iv) no prior history of otologic pathology; v) no pathologically confirmed residual tumor after RT; vi) RT with or without chemotherapy; vii) no malignancy other than NPC; and viii) at least 3 consecutive post-RT MRIs performed at SYSUCC.

 Patients and characteristics

Two clinicians, blinded to the patients' MMD status, independently restaged each patient's pretreatment clinical records using the 8th edition of the International Union against Cancer/American Joint Committee on Cancer staging manual (14). All of the final decisions concerning the different findings were unanimous. Nasopharyngeal recurrence was defined as pathologically confirmed recurrence of a nasopharyngeal tumor. Inflammation markers were measured via blood tests within one week before RT. Ambroxol, budesonide, clarityne, myrtol and nasal irrigation were prescribed during RT.

All patients received intensity-modulated RT (IMRT) or non-IMRT with or without chemotherapy. RT was delivered at 66–70 Gy at 1.8–2 Gy per fraction once a day and five fractions per week. Platinum-based chemotherapy was prescribed, with or without a combination of one or two of the following regimens, including paclitaxel, gemcitabine and fluorouracil.

 Image assessment of MMD

MRI evaluation was performed at 1.5- or 3.0-Tesla MRI units using a standard head coil. The published criteria were used as a measure to evaluate the severity of MMD (15). The severity of MMD was graded according to the high signal of mastoid opacification on T2-weighted MRI as follows: Grade 0 (not detected), Grade 1 (observed <50% air cells involved), and Grade 2 (observed in all mastoid air cells) (Fig. 1A-C) (5,10). Representative MRI scans are shown in Fig. 1. Owing to a discrepancy between the left and right mastoids in patients with NPC, both sides were examined independently for this study. If either the left or right mastoid was classified as Grade 2 MMD (G2MMD), the patient was recorded as Grade 2, which was referred to as severe MMD. The incidence of G2MMD was calculated as follows: Patients with MRI-based G2MMD/total patients at the indicated follow-up period × 100. The missing data were not included in the calculation. The primary endpoint was persistent G2MMD (PG2MMD) after RT, which was defined as at least half of ipsilateral MRI-based MMD scored as Grade 2 after RT (Fig. 1D). When a patient suffered from G2MMD for more than half of the follow-up period, the case was recorded as persistent severe MMD (PG2MMD) (Fig. 1D). The time to event for actuarial analysis of PG2MMD was defined as the time from RT completion to the first occurrence of G2MMD (for the PG2MMD cohort) or to death or the last follow-up (for the non-PG2MMD cohort), whichever occurred first. The MRIs taken at diagnosis, and 3, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months after the end of radiation, were examined. The last follow-up was in December 2022.

 Statistical analysis

The statistical tests were performed using R software (version 4.2.1). The clinical and pathological characteristics and parameters were analyzed with the chi-squared test and t-test. The mean radiation dose to mastoid (mastoid Dmean) and the volume to mastoid (mastoid volume) were transformed into binary variables using the optimal cut-off point based on the area under the receiver operating characteristic (ROC) curve (AUC). The Kaplan-Meier method and the log-rank test were applied to compare patient survival curves among the groups of MMD. The Schoenfeld individual test was used to assess the proportional hazards assumption for the Cox regression model fit. After the validity to assume the proportional hazards, the univariate Cox proportional hazards model was applied to evaluate the association with the time to PG2MMD of patients. Baseline characteristics, inflammation indicators and pretreatment mastoid status before RT, treatment-related factors and drug administration were entered into the model. Missing MRI-based MMD evaluations were retained as missing data and not subjected to statistical imputation. Factors with P<0.200 in the univariate analysis were included into the multivariate Cox regression. The final models were determined by backward stepwise selection. All of the Kaplan-Meier curves of the adjusted Cox model were generated with the R package ‘adjustedCurves’ and the method was ‘conditional’. A value of P<0.05 was considered to indicate statistical significance.

 Results <sec> <title>Clinical characteristics

The sample of patients with NPC consisted of 1,238 eligible patients (915 males and 323 females), with a mean age of 42.82 years (range, 18–76 years) at the time of diagnosis. A total of 275 (22.21%) patients had T1-2 disease and 963 (77.79%) had T3-4 disease. A total of 138 patients (11.15%) were N0 and 1,100 (88.85%) were N1-3 (Table SI). Prior to RT, 271 (21.89%) patients with NPC had G2MMD at diagnosis, whereas 887 (71.65%) did not have any signal of mastoid opacification on MRI. The median post-RT time was 90.56 (range, 6.00–151.86) months. Due to patient compliance and the judgment of the radio-oncologists, not every patient was able to complete all of the post-RT MRI follow-ups. Overall, 8,827 MRI group scans were evaluated, each representing the nasopharyngeal and neck MRIs at the follow-up visits.

 Incidence of post-irradiation MMD

A total of 746 (60.3%) patients were diagnosed with G2MMD at least once after RT. The median post-RT time to develop G2MMD at the first follow-up was 3 (range, 3 to 120) months (data not shown). The peak incidence of G2MMD was at 3 months after RT and continued to decrease thereafter (Fig. S1). The incidences of G2MMD at 3, 6, 12, 24, 60 and 120 months after RT were 35.8% (388/1,083), 28.9% (300/1,039), 26.9% (301/1121), 27.3% (297/1,089), 22.7% (160/706) and 18.8% (6/32), respectively. The incidence of the PG2MMD was 25.5% (316/1,238) in this cohort.

To identify the risk factors for PG2MMD, patients with NPC without MMD pretreatment or local recurrence in the nasopharynx (n=817) were selected. The baseline characteristics are shown in Table I. The mean age was 42.33 years (range, 18–76 years), with 592 male patients. In this cohort, the incidences of G2MMD at 3, 6, 12, 24, 60 and 120 months after RT were 26.2% (187/714), 21.3% (146/687), 21.4% (158/740), 21.4% (153/716), 16.8% (82/487) and 9.5% (2/21), respectively (Fig. 2). The incidence of PG2MMD was 17.9% (146/817).

 Risk factors associated with persistent G2MMD after RT

Radiation dose was reported to be a significant predictor of MMD among the dosimetry factors of RT (2,5,10–12). Patients who received a higher mean dose of RT to the mastoids were more likely to suffer from P2GMMD. However, these indicators related to radiation dose were not measured in a large-scale cohort and none of them were assessed for persistent disease. In addition, it was investigated whether the volume of mastoid (mastoid volume) associated with radiation-induced MMD. Hence, the mastoid Dmean and mastoid volume were transformed into binary variables according to the ROC curves (Table SII). Patients with a mastoid Dmean >37.30 Gy were assigned to the high mastoid Dmean group, while patients with a mastoid volume ≤18.45 mm2 were classified as the low mastoid volume group.

After analyzing the factors affecting MMD aggravation after RT, it was found that smoking, tumor invasion of the ipsilateral wall, the pharyngeal recess (PR), the pharyngeal opening of the eustachian tube (POET), the levator veli palatine muscle (LVPM), the tensor veli palatine muscle (TVPM) and mastoid volume were significant risk factors in the univariate analyses (P<0.05, Table II), but not in the multivariate analyses (P>0.05; Table II). Age, sex and mastoid Dmean were risk factors in both the univariate and multivariate analyses (P<0.05; Fig. 3A and B, Table II).

The ROC curves of age, sex and mastoid Dmean were used to evaluate the prediction efficacy of the final Cox model. The AUC values for the 1-, 2- and 10-year incidences of PG2MMD after RT were 0.894, 0.746 and 0.780, respectively (Fig. S2).

 Discussion

In the present study, the incidences and risk factors for persistent severe MMD in patients with NPC after RT over a long-term period were investigated. Age, sex and mastoid Dmean were favorable factors for developing PG2MMD after radiation in patients with NPC. The location of tumor invasion, inflammatory indicators within one week before RT, targeted therapy and drugs administered during radiation were not significant risk factors for PG2MMD. To the best of our knowledge, this was the largest cohort to report persistent MMD in patients with NPC after RT with long-term follow-up.

The present study revealed similar results for the incidence of severe MMD as reported within the early post-RT period (2–5). The radiation-induced acute response requires a standard 6- to 8-week period to turn over (16). During this period, the tissue around the irradiated nasopharynx swells, which results in a narrow orifice of the eustachian tube and ETD. Deterioration of eustachian tube function persisted and an inflammatory reaction was noted in the upper respiratory tract, including the maxillary sinus and nasopharynx. Unlike OME in patients with NPC at the pre-RT stage, post-RT OME is due to both organic obstruction and functional impairment of the tube. Functional impairment is caused by inflammatory processes within the radiation field due to radiation-induced tissue reactions (i.e., mucositis, desquamation or edema) and tissue damage (i.e., atrophy, fibrosis, degeneration or necrosis) in the radiation-exposed area. The destruction of the effusion evacuation system subsequently causes MMD and contributes to the peak incidence of G2MMD after 3 months of RT. Reactive edema may be gradually absorbed and removed, which leads to a lower incidence of MMD as time progresses. As the acute effect of RT receded, the incidence of G2MMD decreased 3 months after RT.

Patients who received more radiation to the mastoids (a higher mastoid Dmean) from RT were more likely to suffer from PG2MMD. In the long-term study, it was discovered that the mastoid Dmean value was the only significant irradiation factor associated with PG2MMD, and there was a limited difference in the prescribed RT, such as the total dose and fractions (P>0.05), between patients with NPC with and without PG2MMD. Radiation dose was reported to be a significant predictor of MMD among the dose volume factors of RT, but, to the best of our knowledge, it has not been used in a large-scale cohort (2,5,10–12). A mastoid Dmean of 37.30 Gy was suggested as the dose limit for PG2MMD. Both univariate and multivariate analyses revealed that a higher mastoid Dmean was a significant factor associated with PG2MMD (P<0.05). As aforementioned, radiation injury to the eustachian tubal region causes post-irradiation OME, particularly at high radiation doses, and functional impairment is caused by radiation-induced inflammation (2). The destruction of the effusion evacuation system leads to a higher incidence of PG2MMD.

Female patients with NPC were more likely to have PG2MMD (P=0.001), with an HR of 1.594 (95% CI, 1.035 to 2.455) in the multivariate analysis. Anatomic variability in mastoid morphology and sex-specific hormonal profiles may contribute to the differential incidence of PG2MMD. Consistent with a previous study (17), in the present study, significantly smaller mastoid volumes were observed in females than in males (P<0.001), a structural disparity that could increase mechanical vulnerability and reduce mucosal drainage efficiency, potentially elevating PG2MMD susceptibility. In general, estrogens at physiological concentrations are thought to play an immune-stimulating role by upregulating both cellular and humoral immunity, whereas androgens have an anti-inflammatory effect (18). This interplay between anatomic constraints and hormonally mediated immune regulation may contribute to sex-specific disparities in the incidence of PG2MMD.

Patients with NPC aged >50 years at diagnosis were more likely to have PG2MMD (P=0.016), with an HR of 1.699 (95% CI, 1.105 to 2.613). An age-related decline in immune function (19) increases susceptibility to infections. Comorbidities, such as diabetes, hypertension and cardiovascular disease, which impair microvascular circulation and tissue repair ability, are common in older patients. These factors collectively exacerbate radiation-induced damage in the mastoid region, disrupting mucosal integrity and increasing the risk of MMD. The interplay of immunosenescence, chronic inflammation from comorbidities and the cytotoxic effect of radiation creates a pathophysiological cascade that compromises the regenerative capacity of the mastoid, facilitating MMD progression.

Notably, the indicators of tumor invasion, including invasion of the ipsilateral wall, the PR, POET, LVPM, TVPM and the T stage (P>0.05), were not able to predict PG2MMD in the multivariate analyses. These results indicated that the tumor invasion before RT did not influence the incidence of PG2MMD directly due to the involvement of various complex factors and changes in nasopharyngeal tissues after RT.

Remarkably, no drug applied during RT was a significant risk factor for PG2MMD. In addition to the lack of efficacy of anti-EGFR therapy (P>0.05), the application of ambroxol, budesonide, clarityne, myrtol or nasal irrigation during RT played a significant role in PG2MMD (P>0.05). Histopathological images of otomastoiditis samples revealed numerous vessels involved in angiogenesis (20), suggesting that antiangiogenic therapy, as a targeted therapy, may play a role in PG2MMD. Ambroxol therapy is a safe proven cough linctus and has improved the therapeutic effect of secretory otitis media, one of whose complications is MMD (21,22). Hence, it was hypothesized that ambroxol prevented irradiated patients with NPC from developing PG2MMD. In contrast to expectations, neither targeted therapy nor ambroxol influenced the incidence of P2GMMD after RT in patients with NPC. The reasons may be as follows: First, the effects of these drugs were not as lasting as those of radiation. Furthermore, the drug combination could affect the treatment of secretory otitis media. For instance, the addition of ambroxol reduces tympanic pressure after glucocorticoid treatment (22), which is not commonly applied in the treatment of NPC due to lacking anti-tumor properties. In addition, the role of the above medications in nasopharyngeal ciliary motility remains elusive, even though certain drugs serve as mucolytic agents in respiratory diseases (21). To conclude, the use of medicine to relieve PG2MMD requires further investigation.

Inflammatory indicators within one week before RT, such as the WBC count, neutrophil count, SAA, CRP and LDH, did not show any utility in predicting PG2MMD (P>0.05). The inflammation indicators reflect the status of the whole body; therefore, they may not be correlated with regional inflammation, such as nasal cavity stenosis and atresia (23), and MMD.

There were several limitations to this study. First, no audiometric findings were analyzed because our center restarted audiometry tests beginning in 2023. The omission of audiometric data weakens the study's ability to fully characterize MMD-related disease, assess treatment efficacy and inform holistic patient care. This highlights a gap in understanding the functional consequences of the disease to a certain extent. Second, even though the results were obtained from patients from prospective cohorts, they were based on retrospective groups, leading to biases, data quality issues and challenges in establishing causality. Third, treatments for severe MMD were not fully included in this study. The treatments for post-irradiation OME include simple tympanic aspiration, incisional myringotomy, ventilation tube insertion and laser myringotomy. As the cancer center, we were unable to perform surgery, such as mastoidectomy to severe MMD due to a lack of specialists for the mastoid. Hence, cooperation between our center and the general hospital with the otolaryngology head and neck department is necessary. Finally, no efficient medicines have been shown to improve PGMMD. Future studies should integrate audiometric assessments to address these gaps and better align findings with patient-centered outcomes.

In conclusion, for patients with NPC after irradiation, the peak incidence of G2MMD occurred at the 3 months after RT and decreased thereafter. Female sex, advanced age at diagnosis and high mastoid Dmean were significant risk factors for PG2MMD, which has potential risks leading to sensorineural/mixed hearing loss. Thus, clinicians should consider appropriate strategies to reverse the inflammatory reaction.

 Supplementary Material Supporting Data Supporting Data Acknowledgements

Not applicable.

 Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

 Authors' contributions

RLX was involved in the conceptualization, methodology, formal analysis, investigation, data curation, writing and revising the original draft, and funding acquisition. SYC contributed by performing formal analysis and investigation. ZKF, WBW, XTD, JHW and RY contributed to data collection and interpretation. SYF and PH taught other authors how to recognize and evaluate images of mastoid mucosa disease and performed data interpretation. CYD and CL selected the methods of statistical analysis used in the study and performed data interpretation. BL interpreted the data and wrote the original draft of the manuscript. RLX and SYC confirm the authenticity of all the raw data. WHJ was involved in the study conceptualization, resources and supervision. MYC contributed to the study conceptualization, supervision, project administration and funding acquisition. YPL was involved in the conceptualization and supervision of the study. All authors have read and approved the final manuscript.

 Ethics approval and consent to participate

This retrospective cohort study was approved and the written informed consents were waived by the ethics committee of SYSUCC (Guangzhou, China; Institutional Review Board no. B2023-050-01).

 Patient consent for publication

The patients provided written informed consent for the publication of accompanying images.

 Competing interests

The authors declare that they have no competing interests.

 References ChenYPChanATCLeQTBlanchardPSunYMaJNasopharyngeal carcinomaLancet3946480201910.1016/S0140-6736(19)30956-031178151 BhandareNAntonelliPJMorrisCGMalayapaRSMendenhallWMOtotoxicity after radiotherapy for head and neck tumorsInt J Radiat Oncol Biol Phys67469479200710.1016/j.ijrobp.2006.09.01717236969 YaoJJZhouGQYuXLTangLLChenLMaoYPLinLZhangLLShaoJYGuoYIncidence of and risk factors for mastoiditis after intensity modulated radiotherapy in nasopharyngeal carcinomaPLoS One10e0131284201510.1371/journal.pone.013128426114761 KewJTongMCKingADLeungSFMetreweliCvan HasseltCAMagnetic resonance imaging and audiologic assessment of middle ear effusions in patients with nasopharyngeal carcinoma before radiation therapyAm J Otol20747619999918177 NishimuraRBabaYMurakamiRBabaTFurusawaMIshikawaTUshioYTakahashiMMR evaluation of radiation otomastoiditisInt J Radiat Oncol Biol Phys39155160199710.1016/S0360-3016(97)00302-79300750 McDonaldMHHoffmanMRGentryLRWhen is fluid in the mastoid cells a worrisome finding?J Am Board Fam Med26218220201310.3122/jabfm.2013.02.12019023471938 JoseJCoatesworthAPAnthonyRReillyPGLife threatening complications after partially treated mastoiditisBMJ3274142200310.1136/bmj.327.7405.4112842957 ChenJFLeeSTNasopharyngeal carcinoma presenting as an intracranial abscessSurg Neurol49553557199810.1016/S0090-3019(97)00298-X9586935 KingADKewJTongMLeungSFLamWWMetreweliCvan HasseltCAMagnetic resonance imaging of the eustachian tube in nasopharyngeal carcinoma: Correlation of patterns of spread with middle ear effusionAm J Otol20697319999918176 YaoJJZhouGQLinLZhangWJPengYLChenLTangLLMaoYPMaJSunYDose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinomaSci Rep513525201510.1038/srep1352526323586 WalkerGVAhmedSAllenPGidleyPWWooSYDeMonteFChangELMahajanARadiation-induced middle ear and mastoid opacification in skull base tumors treated with radiotherapyInt J Radiat Oncol Biol Phys81e819e823201110.1016/j.ijrobp.2010.11.04721277110 YaoJJZhouGQJinYNZhangWJLinLYuXLShaoJYMaJSunYPredictors of mastoiditis after intensity-modulated radiotherapy in nasopharyngeal carcinoma: A dose-volume analysisJ Cancer7276282201610.7150/jca.1318326918040 WangTMShenGPChenMYZhangJBSunYHeJXueWQLiXZHuangSYZhengXHGenome-wide association study of susceptibility loci for radiation-induced brain injuryJ Natl Cancer Inst111620628201910.1093/jnci/djy15030299488 AminMBEdgeSBGreeneFLByrdDRBrooklandRKWashingtonMKGershenwaldJEComptonCCHessKRSullivanDCAJCC Cancer Staging ManualSpringerHeidelberg2017 SaatRMahmoodGLaulajainen-HongistoALempinenLAarnisaloAAJeroJMarkkolaAComparison of MR imaging findings in paediatric and adult patients with acute mastoiditis and incidental intramastoid bright signal on T2-weighted imagesEur Radiol2626322639201610.1007/s00330-015-4113-526607577 HalperinEWazerDPerezCBradyLPerez & Brady's Principles and Practice of Radiation OncologyLippincott Williams & Wilkins (LWW)Philadelphia, PA2018 BoussaidMBrahimOBouanenIKenaniMLimemHMahjoubYMesratiMAAissaouiASex determination by Ct -scan analysis of the mastoid bone: A cross-sectional studyHeliyon10e33712202410.1016/j.heliyon.2024.e3371239050434 YalcinkayaAYalcinkayaRSardhFLandegrenNImmune dynamics throughout life in relation to sex hormones and perspectives gained from gender-affirming hormone therapyFront Immunol151501364202510.3389/fimmu.2024.150136439885993 KaiserMSemeraroMDHerrmannMAbsengerGGergerARennerWImmune aging and immunotherapy in cancerInt J Mol Sci227016202110.3390/ijms2213701634209842 PopescuCIoniţăEMogoantăCASimionescuCPătruEClinical and histopathological aspects in otomastoiditisRom J Morphol Embryol50453460200919690774 MullinSSmithLLeeKD'SouzaGWoodgatePElfleinJHällqvistJToffoliMStreeterAHoskingJAmbroxol for the treatment of patients with parkinson disease with and without glucocerebrosidase gene mutations: A nonrandomized, noncontrolled trialJAMA Neurol77427434202010.1001/jamaneurol.2019.461131930374 ZhouXJinXYangLWeiXEfficacy and safety of ambroxol hydrochloride in the treatment of secretory otitis media: A systematic review and meta-analysisAnn Transl Med10142202210.21037/atm-22-23735284532 YanJJGuoSSLinDFLiuLTLiuSLXiaoBBYangJHWenDXYangZCLiangYJDevelopment and validation of a normal tissue complication probability model for acquired nasal cavity stenosis and atresia after radical radiotherapy for nasopharyngeal carcinomaRadiother Oncol160917202110.1016/j.radonc.2021.03.04033839205

MRI images of criteria and flowchart of patient selection and study design. Representative MRIs of patients with (A) Grade 0, (B) Grade 1 and (C) Grade 2 MMD (arrows) after RT. Patients were stratified according to the presence or absence of PG2MMD, which referred to at least half of ipsilateral MRI-based mastoiditis scored Grade 2 after RT in patients with NPC. (D) Flow chart of patient inclusion. The GARTP study (ChiCTRROC-17012658) is a prospective observational clinical trial. NPC, nasopharyngeal carcinoma; RT, radiotherapy; PG2MMD, persistent grade 2 mastoid mucosa disease; MMD, mastoid mucosa disease.

Figure 1. MRI images of criteria and flowchart of patient selection and study design. Representative MRIs of patients with (A) Grade 0, (B) Grade 1 and (C) Grade 2 MMD (arrows) after RT. Patients were...

Frequency of mastoid mucosa disease in patients with nasopharyngeal carcinoma after radiotherapy. p, pretreatment.

Figure 2. Frequency of mastoid mucosa disease in patients with nasopharyngeal carcinoma after radiotherapy. p, pretreatment.

Risk factors for PG2MMD after RT in patients with NPC. Cumulative event rate of PG2MMD with post-RT time for patients with NPC stratified by (A) sex and (B) mastoid Dmean. PG2MMD, persistent grade 2 mastoid mucosa disease; NPC, nasopharyngeal carcinoma; RT, radiotherapy; Dmean, mean dose to the ipsilateral mastoid.

Figure 3. Risk factors for PG2MMD after RT in patients with NPC. Cumulative event rate of PG2MMD with post–RT time for patients with NPC stratified by (A) sex and (B) mastoid Dmean. PG2MMD, persistent...

Baseline characteristics of patients with nasopharyngeal carcinoma without pretreatment mastoid mucosa disease or nasopharyngeal recurrence (n=817).

Characteristic Value
Age, years 42.33±10.45
Male sex 592 (72.5)
Ear symptom 237 (29.0)
Allergy history 55 (6.7)
Smoking 224 (27.4)
BMI, kg/m2 23.07±3.4
T stage
  1-2 219 (26.8)
  3-4 598 (73.2)
N stage
  0 106 (13.0)
  1-3 711 (87.0)
TNM stage
  I–II 134 (16.4)
  III–IV 683 (83.6)
Ipsilateral wall 516 (63.2)
PR 565 (69.2)
POET 213 (26.1)
LVPM 365 (44.7)
TVPM 183 (22.4)
IMRT 778 (95.2)
Mastoid Dmean, Gy 36.12±5.59
Mastoid volume, mm2 14.43±4.88
Total dose, Gy 69.72±1.10
Total fractions 30.97±1.31
Chemotherapy 747 (91.4)
Target therapy 142 (17.4)
Budesonide 347 (42.5)
Ambroxol 490 (60.0)
Myrtol 157 (19.2)
Clarityne 82 (10.0)
Nasal irrigation 418 (51.2)
WBC, ×109/l 6.01±2.37
Neutrophils, ×109/l 3.69±2.02
Monocytes, ×109/l 0.51±1.94
Lymphocytes, ×109/l 1.73±0.66
Eosinophils, ×109/l 0.12±0.12
SAA, mg/l 11.51±36.86
CRP, mg/l 4.11±9.33
LDH, U/l 176.15±46.33

Values are expressed as the mean ± standard deviation or n (%). BMI, body mass index; PR, pharyngeal recess; POET, pharyngeal opening of eustachian tube; LVPM, levator veli palatine muscle; TVPM, tensor veli palatine muscle; IMRT, intensity-modulated radiotherapy; mastoid Dmean, mean dose to the ipsilateral mastoid; WBC, white blood cell; SAA, serum amyloid A; CRP, C-reaction protein; LDH, lactate dehydrogenase.

Prognostic factors of persistent grade 2 mastoid mucosa disease by univariate and multivariate analyses for patients with nasopharyngeal without pretreatment mastoiditis or local recurrence in the nasopharynx.

Univariate analyses Multivariate analyses
Factor HR 95% CI P-value HR 95% CI P-value
Age (≤50 vs. >50 years) 1.366 0.94–1.984 0.102 1.699 1.105–2.613 0.016
Sex (male vs. female) 1.766 1.266–2.463 0.001 1.594 1.035–2.455 0.034
Ear symptom(s) (no vs. yes) 0.756 0.519–1.102 0.146 0.651 0.418–1.013 0.057
Smoking (no vs. yes) 0.632 0.419–0.954 0.029 0.738 0.445–1.225 0.240
Allergy (no vs. yes) 1.621 0.950–2.765 0.077 1.504 0.827–2.734 0.181
BMI (kg/m2) 1.011 0.965–1.060 0.641 - - -
T stage (1–2 vs. 3–4) 1.242 0.849–1.818 0.265 - - -
N stage (0 vs. 1–3) 1.182 0.713–1.961 0.516 - - -
TNM stage (I–II vs. III–IV) 0.992 0.645–1.527 0.972 - - -
Ipsilateral wall 1.771 1.220–2.572 0.003 0.895 0.505–1.584 0.703
PR 2.080 1.369–3.160 0.001 1.884 0.986–3.601 0.055
POET 2.083 1.497–2.896 <0.001 1.280 0.780–2.102 0.329
LVPM 1.990 1.428–2.774 <0.001 0.822 0.463–1.458 0.502
TVPM 2.283 1.632–3.192 <0.001 1.383 0.818–2.337 0.226
Radiation technique 0.983 0.460–2.100 0.964 - - -
(non-IMRT vs. IMRT)
Mastoid Dmean 1.756 1.222–2.522 0.002 1.554 1.050–2.298 0.027
(≤37.30 vs. >37.30 Gy)
Mastoid volume 0.546 0.312–0.956 0.034 0.772 0.433–1.376 0.380
(≤18.45 vs. >18.45 mm2)
Total dose (cGy) 1.002 1.000–1.003 0.066 1.001 0.998–1.003 0.639
Total Fractions 1.034 0.915–1.169 0.593 - - -
Chemotherapy (no vs. yes) 1.315 0.692–2.500 0.403 - - -
Targeted therapy (no vs. yes) 1.304 0.600–2.835 0.503 - - -
Ambroxol (yes vs. no) 1.187 0.846–1.665 0.321 - - -
Budesonide (yes vs. no) 1.197 0.864–1.659 0.278 - - -
Clarityne (yes vs. no) 0.830 0.470–1.468 0.522 - - -
Myrtol (yes vs. no) 1.288 0.877–1.891 0.197 1.177 0.756–1.832 0.471
Nasal irrigation (yes vs. no) 0.921 0.665–1.274 0.617 - - -
WBC (×109/l) 0.981 0.913–1.054 0.597 - - -
Neutrophils (×109/l) 0.994 0.916–1.079 0.89 - - -
Lymphocytes (×109/l) 0.808 0.625–1.044 0.102 0.946 0.705–1.270 0.714
Monocytes (×109/l) 0.974 0.820–1.158 0.769 - - -
Eosinophils (×109/l) 0.883 0.212–3.683 0.865 - - -
SAA (mg/l) 0.998 0.979–1.018 0.838 - - -
CRP (mg/l) 1.000 0.996–1.003 0.918 - - -
LDH (U/l) 0.983 0.930–1.038 0.529 - - -

BMI, body mass index; PR, pharyngeal recess; POET, pharyngeal opening of eustachian tube; LVPM, levator veli palatine muscle; TVPM, tensor veli palatine muscle; IMRT, intensity-modulated radiotherapy; mastoid Dmean, mean dose to the ipsilateral mastoid; WBC, white blood cell; SAA, serum amyloid A; CRP, C-reaction protein; LDH, lactate dehydrogenase.